Cargando…

Early onset esophageal adenocarcinoma: a distinct molecular entity?

Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly with a median age of 68 years. The incidence of EAC has been rising over the last decades, also among young adults. The aim of the study was to investigate whether early onset EAC is a distinct molecular entity. To identify early onse...

Descripción completa

Detalles Bibliográficos
Autores principales: van Nistelrooij, Anna M.J., van Marion, Ronald, Biermann, Katharina, Spaander, Manon C.W., van Lanschot, J. Jan B., Wijnhoven, Bas P.L., Dinjens, Winand N.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751915/
https://www.ncbi.nlm.nih.gov/pubmed/26973859
_version_ 1782415651985424384
author van Nistelrooij, Anna M.J.
van Marion, Ronald
Biermann, Katharina
Spaander, Manon C.W.
van Lanschot, J. Jan B.
Wijnhoven, Bas P.L.
Dinjens, Winand N.M.
author_facet van Nistelrooij, Anna M.J.
van Marion, Ronald
Biermann, Katharina
Spaander, Manon C.W.
van Lanschot, J. Jan B.
Wijnhoven, Bas P.L.
Dinjens, Winand N.M.
author_sort van Nistelrooij, Anna M.J.
collection PubMed
description Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly with a median age of 68 years. The incidence of EAC has been rising over the last decades, also among young adults. The aim of the study was to investigate whether early onset EAC is a distinct molecular entity. To identify early onset EACs, the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) was searched. Twenty-eight tumors of patients aged ≤40 years were selected and matched with 27 tumors of patients aged ≥68 years. DNA was isolated from surgically resected specimen and sequenced on the Ion Torrent Personal Genome Machine with the Ion AmpliSeq Cancer Panel. No differences in mutational load between early onset and conventional EACs were observed (P=0.196). The most frequently mutated genes were TP53 (73%) and P16 (16%). Additional mutations in early onset EACs occurred exclusively in: APC, CDH1, CTNNB1, FGFR2, and STK11. In the conventional EACs additional mutations were exclusively identified in: ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4, and VHL. Additional mutations besides TP53 and P16 seem to occur in different genes related to cell fate pathways for early onset EACs, while the additional mutations in conventional EACs are related to survival pathways.
format Online
Article
Text
id pubmed-4751915
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47519152016-03-11 Early onset esophageal adenocarcinoma: a distinct molecular entity? van Nistelrooij, Anna M.J. van Marion, Ronald Biermann, Katharina Spaander, Manon C.W. van Lanschot, J. Jan B. Wijnhoven, Bas P.L. Dinjens, Winand N.M. Oncoscience Research Paper Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly with a median age of 68 years. The incidence of EAC has been rising over the last decades, also among young adults. The aim of the study was to investigate whether early onset EAC is a distinct molecular entity. To identify early onset EACs, the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA) was searched. Twenty-eight tumors of patients aged ≤40 years were selected and matched with 27 tumors of patients aged ≥68 years. DNA was isolated from surgically resected specimen and sequenced on the Ion Torrent Personal Genome Machine with the Ion AmpliSeq Cancer Panel. No differences in mutational load between early onset and conventional EACs were observed (P=0.196). The most frequently mutated genes were TP53 (73%) and P16 (16%). Additional mutations in early onset EACs occurred exclusively in: APC, CDH1, CTNNB1, FGFR2, and STK11. In the conventional EACs additional mutations were exclusively identified in: ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4, and VHL. Additional mutations besides TP53 and P16 seem to occur in different genes related to cell fate pathways for early onset EACs, while the additional mutations in conventional EACs are related to survival pathways. Impact Journals LLC 2016-02-01 /pmc/articles/PMC4751915/ /pubmed/26973859 Text en Copyright: © 2016 van Nistelrooij et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
van Nistelrooij, Anna M.J.
van Marion, Ronald
Biermann, Katharina
Spaander, Manon C.W.
van Lanschot, J. Jan B.
Wijnhoven, Bas P.L.
Dinjens, Winand N.M.
Early onset esophageal adenocarcinoma: a distinct molecular entity?
title Early onset esophageal adenocarcinoma: a distinct molecular entity?
title_full Early onset esophageal adenocarcinoma: a distinct molecular entity?
title_fullStr Early onset esophageal adenocarcinoma: a distinct molecular entity?
title_full_unstemmed Early onset esophageal adenocarcinoma: a distinct molecular entity?
title_short Early onset esophageal adenocarcinoma: a distinct molecular entity?
title_sort early onset esophageal adenocarcinoma: a distinct molecular entity?
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751915/
https://www.ncbi.nlm.nih.gov/pubmed/26973859
work_keys_str_mv AT vannistelrooijannamj earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT vanmarionronald earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT biermannkatharina earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT spaandermanoncw earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT vanlanschotjjanb earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT wijnhovenbaspl earlyonsetesophagealadenocarcinomaadistinctmolecularentity
AT dinjenswinandnm earlyonsetesophagealadenocarcinomaadistinctmolecularentity